Skip to content

Vertex Pharmaceuticals’ Orphan Drug Kalydeco (Ivacaftor) + VX-809 Final Phase II Results (Poster #260)

October 11, 2012


       The highly anticipated data from the Phase II combination study of unapproved VX-809 and approved orphan drug Kalydeco (Ivacaftor), in CF patients, who have the most common genetic mutation (F508del), was presented on October 11, 2012 at the North American CF Conference (NACFC).   

       The lead study investigator, Michael P. Boyle, M.D., F.C.C.P., Associate Professor, Director of Johns Hopkins Adult Cystic Fibrosis (CF) Center, presented the final study results at Poster Session I, Poster #260.  

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: